BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71. [PMID: 22047105 DOI: 10.1186/1750-1172-6-71] [Cited by in Crossref: 179] [Cited by in F6Publishing: 129] [Article Influence: 17.9] [Reference Citation Analysis]
Number Citing Articles
1 Tang Z, Akhter S, Ramprasad A, Wang X, Reibarkh M, Wang J, Aryal S, Thota SS, Zhao J, Douglas JT, Gao P, Holmstrom ED, Miao Y, Wang J. Recognition of single-stranded nucleic acids by small-molecule splicing modulators. Nucleic Acids Res 2021:gkab602. [PMID: 34283224 DOI: 10.1093/nar/gkab602] [Reference Citation Analysis]
2 Veltrop M, Aartsma-Rus A. Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases. Exp Cell Res 2014;325:50-5. [PMID: 24486759 DOI: 10.1016/j.yexcr.2014.01.026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
3 Tan H, Gu T, Chen E, Punekar R, Shieh PB. Healthcare Utilization, Costs of Care, and Mortality Among Psatients With Spinal Muscular Atrophy. J Health Econ Outcomes Res 2019;6:185-95. [PMID: 32685590 DOI: 10.36469/63185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Hensel N, Kubinski S, Claus P. The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs. Front Neurol 2020;11:45. [PMID: 32117013 DOI: 10.3389/fneur.2020.00045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
5 Simone C, Ramirez A, Bucchia M, Rinchetti P, Rideout H, Papadimitriou D, Re DB, Corti S. Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications? Cell Mol Life Sci 2016;73:1003-20. [PMID: 26681261 DOI: 10.1007/s00018-015-2106-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
6 Bortolani S, Stura G, Ventilii G, Vercelli L, Rolle E, Ricci F, Bergui M, Mongini T. Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: Transforaminal versus conventional approach. Neuromuscul Disord 2019;29:742-6. [PMID: 31604650 DOI: 10.1016/j.nmd.2019.08.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
7 Coratti G, Pera MC, Montes J, Pasternak A, Scoto M, Baranello G, Messina S, Dunaway Young S, Glanzman AM, Duong T, De Sanctis R, Mazzone ES, Milev E, Rohwer A, Civitello M, Pane M, Antonaci L, Frongia AL, Sframeli M, Vita GL, DʼAmico A, Mizzoni I, Albamonte E, Darras BT, Bertini E, Sansone VA, Bovis F, Day J, Bruno C, Muntoni F, De Vivo DC, Finkel R, Mercuri E. Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle Nerve 2021. [PMID: 34327716 DOI: 10.1002/mus.27384] [Reference Citation Analysis]
8 Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Adv Ther 2019;36:1164-76. [PMID: 30879249 DOI: 10.1007/s12325-019-00923-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 16.0] [Reference Citation Analysis]
9 Kimura S, Harashima H. Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB. Pharmaceutics 2020;12:E1216. [PMID: 33334049 DOI: 10.3390/pharmaceutics12121216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zanetta C, Riboldi G, Nizzardo M, Simone C, Faravelli I, Bresolin N, Comi GP, Corti S. Molecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA). J Cell Mol Med 2014;18:187-96. [PMID: 24400925 DOI: 10.1111/jcmm.12224] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
11 Osmanovic A, Ranxha G, Kumpe M, Müschen L, Binz C, Wiehler F, Paracka L, Körner S, Kollewe K, Petri S, Schreiber-Katz O. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. J Neurol 2020;267:2398-407. [PMID: 32361837 DOI: 10.1007/s00415-020-09847-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
12 Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, Walter MC, Nagels KH. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11:58. [PMID: 27145956 DOI: 10.1186/s13023-016-0424-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
13 Finkel RS, Schara-Schmidt U, Hagenacker T. Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy. Front Neurol 2020;11:783. [PMID: 32849232 DOI: 10.3389/fneur.2020.00783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Brogna C, Cristiano L, Verdolotti T, Pichiecchio A, Cinnante C, Sansone V, Sconfienza LM, Berardinelli A, Garibaldi M, Antonini G, Pane M, Pera MC, Antonaci L, Ficociello L, Albamonte E, Tasca G, Begliuomini C, Tartaglione T, Maggi L, Govoni A, Comi G, Colosimo C, Mercuri E. MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients. J Neurol 2020;267:898-912. [DOI: 10.1007/s00415-019-09646-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
15 Sharifi Z, Taheri M, Fallah MS, Abiri M, Golnabi F, Bagherian H, Zeinali R, Farahzadi H, Alborji M, Tehrani PG, Amini M, Asnavandi S, Hashemi M, Forouzesh F, Zeinali S. Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran. J Mol Neurosci 2021. [PMID: 33481221 DOI: 10.1007/s12031-020-01789-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Bertoli S, De Amicis R, Mastella C, Pieri G, Giaquinto E, Battezzati A, Leone A, Baranello G. Spinal Muscular Atrophy, types I and II: What are the differences in body composition and resting energy expenditure? Clin Nutr 2017;36:1674-80. [PMID: 27890489 DOI: 10.1016/j.clnu.2016.10.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
17 Menduti G, Rasà DM, Stanga S, Boido M. Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment. Front Pharmacol 2020;11:592234. [PMID: 33281605 DOI: 10.3389/fphar.2020.592234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Rose L, McKim D, Leasa D, Nonoyama M, Tandon A, Bai YQ, Goldstein R, Amin R, Katz S, Gershon A. Respiratory health service utilization of children with neuromuscular disease. Pediatr Pulmonol 2018;53:1378-86. [PMID: 30129703 DOI: 10.1002/ppul.24145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Berti B, Fanelli L, de Sanctis R, Onesimo R, Palermo C, Leone D, Carnicella S, Norcia G, Forcina N, Coratti G, Giorgio V, Cerchiari A, Lucibello S, Finkel R, Pane M, Mercuri E. Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module. J Neuromuscul Dis 2021;8:589-601. [PMID: 34024771 DOI: 10.3233/JND-200614] [Reference Citation Analysis]
20 Wang XB, Cui NH, Gao JJ, Qiu XP, Zheng F. SMN1 duplications contribute to sporadic amyotrophic lateral sclerosis susceptibility: evidence from a meta-analysis. J Neurol Sci 2014;340:63-8. [PMID: 24630593 DOI: 10.1016/j.jns.2014.02.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
21 Schellino R, Boido M, Borsello T, Vercelli A. Pharmacological c-Jun NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice. Front Mol Neurosci 2018;11:308. [PMID: 30233310 DOI: 10.3389/fnmol.2018.00308] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
22 Santosa KB, Keane AM, Jablonka-Shariff A, Vannucci B, Snyder-Warwick AK. Clinical relevance of terminal Schwann cells: An overlooked component of the neuromuscular junction. J Neurosci Res 2018;96:1125-35. [PMID: 29536564 DOI: 10.1002/jnr.24231] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
23 Tauchert MJ, Ficner R. Structural analysis of the spliceosomal RNA helicase Prp28 from the thermophilic eukaryote Chaetomium thermophilum. Acta Crystallogr F Struct Biol Commun 2016;72:409-16. [PMID: 27139834 DOI: 10.1107/S2053230X16006038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Montes J, Dunaway Young S, Mazzone ES, Pasternak A, Glanzman AM, Finkel RS, Darras BT, Muntoni F, Mercuri E, De Vivo DC, Bishop KM, Schneider E, Bennett CF, Foster R, Farwell W; CS2 and CS12 Study Groups. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve 2019;60:409-14. [PMID: 31298747 DOI: 10.1002/mus.26633] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
25 Baranello G, Vai S, Broggi F, Masson R, Arnoldi MT, Zanin R, Mastella C, Bianchi ML. Evolution of bone mineral density, bone metabolism and fragility fractures in Spinal Muscular Atrophy (SMA) types 2 and 3. Neuromuscular Disorders 2019;29:525-32. [DOI: 10.1016/j.nmd.2019.06.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
26 Kevadiya BD, Ottemann BM, Thomas MB, Mukadam I, Nigam S, McMillan J, Gorantla S, Bronich TK, Edagwa B, Gendelman HE. Neurotheranostics as personalized medicines. Adv Drug Deliv Rev 2019;148:252-89. [PMID: 30421721 DOI: 10.1016/j.addr.2018.10.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
27 Abati E, Corti S. Pregnancy outcomes in women with spinal muscular atrophy: A review. Journal of the Neurological Sciences 2018;388:50-60. [DOI: 10.1016/j.jns.2018.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Rizzacasa B, Morini E, Pucci S, Murdocca M, Novelli G, Amati F. LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies. Int J Mol Sci 2017;18:E290. [PMID: 28146073 DOI: 10.3390/ijms18020290] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
29 Ahmad S, Bhatia K, Kannan A, Gangwani L. Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy. J Exp Neurosci 2016;10:39-49. [PMID: 27042141 DOI: 10.4137/JEN.S33122] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
30 Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis 2021;16:47. [PMID: 33485382 DOI: 10.1186/s13023-021-01695-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
31 Hadwen J, MacKenzie D, Shamim F, Mongeon K, Holcik M, MacKenzie A, Farooq F. VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models. Orphanet J Rare Dis 2014;9:4. [PMID: 24405637 DOI: 10.1186/1750-1172-9-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
32 Zhao M, Lian M, Cheah FSH, Tan ASC, Agarwal A, Chong SS. Identification of Novel Microsatellite Markers Flanking the SMN1 and SMN2 Duplicated Region and Inclusion Into a Single-Tube Tridecaplex Panel for Haplotype-Based Preimplantation Genetic Testing of Spinal Muscular Atrophy. Front Genet 2019;10:1105. [PMID: 31781167 DOI: 10.3389/fgene.2019.01105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Fogarty MJ. Driven to decay: Excitability and synaptic abnormalities in amyotrophic lateral sclerosis. Brain Res Bull 2018;140:318-33. [PMID: 29870780 DOI: 10.1016/j.brainresbull.2018.05.023] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 12.3] [Reference Citation Analysis]
34 Sansone VA, Coratti G, Pera MC, Pane M, Messina S, Salmin F, Albamonte E, De Sanctis R, Sframeli M, Di Bella V, Morando S, d'Amico A, Frongia AL, Antonaci L, Pirola A, Pedemonte M, Bertini E, Bruno C, Mercuri E; Italian ISMAC group. Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen. Eur J Neurol 2021;28:602-8. [PMID: 33012052 DOI: 10.1111/ene.14567] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bruno G, Donnarumma B, Inverardi A, Buonpensiero P, Sepe A, Tosco A, Raia V, Varone A. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1. Pediatr Pulmonol 2021;56:1806-8. [PMID: 33684256 DOI: 10.1002/ppul.25334] [Reference Citation Analysis]
36 Lloyd AJ, Thompson R, Gallop K, Teynor M. Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy. Clinicoecon Outcomes Res 2019;11:615-22. [PMID: 31749625 DOI: 10.2147/CEOR.S214084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
37 Rashnonejad A, Chermahini GA, Li S, Ozkinay F, Gao G. Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene. Mol Biotechnol 2016;58:30-6. [PMID: 26607476 DOI: 10.1007/s12033-015-9899-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
38 Pro S, Tozzi AE, D'Amico A, Catteruccia M, Cherchi C, De Luca M, Nicita F, Diodato D, Cutrera R, Bertini E, Valeriani M. Age-related sensory neuropathy in patients with spinal muscular atrophy type 1. Muscle Nerve 2021. [PMID: 34368972 DOI: 10.1002/mus.27389] [Reference Citation Analysis]
39 Rademacher S, Verheijen BM, Hensel N, Peters M, Bora G, Brandes G, Vieira de Sá R, Heidrich N, Fischer S, Brinkmann H, van der Pol WL, Wirth B, Pasterkamp RJ, Claus P. Metalloprotease-mediated cleavage of PlexinD1 and its sequestration to actin rods in the motoneuron disease spinal muscular atrophy (SMA). Hum Mol Genet 2017;26:3946-59. [PMID: 29016853 DOI: 10.1093/hmg/ddx282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
40 Walter LM, Deguise MO, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, Hazell G, McFall E, Kordala A, Hammond SM, Abendroth F, Murray LM, Shorrock HK, Prosdocimo DA, Haldar SM, Jain MK, Gillingwater TH, Claus P, Kothary R, Wood MJA, Bowerman M. Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. EBioMedicine 2018;31:226-42. [PMID: 29735415 DOI: 10.1016/j.ebiom.2018.04.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
41 Savini G, Asteggiano C, Paoletti M, Parravicini S, Pezzotti E, Solazzo F, Muzic SI, Santini F, Deligianni X, Gardani A, Germani G, Farina LM, Bergsland N, Gandini Wheeler-Kingshott CAM, Berardinelli A, Bastianello S, Pichiecchio A. Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment? Front Neurol 2021;12:613834. [PMID: 33854470 DOI: 10.3389/fneur.2021.613834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Facini C, Spagnoli C, Pisani F. Epileptic and non-epileptic paroxysmal motor phenomena in newborns. The Journal of Maternal-Fetal & Neonatal Medicine 2016;29:3652-9. [DOI: 10.3109/14767058.2016.1140735] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
43 Faravelli I, Nizzardo M, Comi GP, Corti S. Spinal muscular atrophy--recent therapeutic advances for an old challenge. Nat Rev Neurol 2015;11:351-9. [PMID: 25986506 DOI: 10.1038/nrneurol.2015.77] [Cited by in Crossref: 88] [Cited by in F6Publishing: 72] [Article Influence: 14.7] [Reference Citation Analysis]
44 Mercuri E, Finkel R, Scoto M, Hall S, Eaton S, Rashid A, Balashkina J, Coratti G, Pera MC, Samsuddin S, Civitello M, Muntoni F, De Vivo DC, Darras BT, Day J, Montes J, Glanzmann A, Pasternack A, Salazar R, Dunaway Young S, Duong T, Pane M, Berti B, Palermo C, Leone D, Frongia A, Antonaci L, De Sanctis R, Messina S, Bertini E, Vita G, Bruno C, Sframeli M, Sansone VA, Albamonte E, D'amico A. Development of an academic disease registry for spinal muscular atrophy. Neuromuscular Disorders 2019;29:794-9. [DOI: 10.1016/j.nmd.2019.08.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
45 Siller S, Kasem R, Witt TN, Tonn JC, Zausinger S. Painless motor radiculopathy of the cervical spine: clinical and radiological characteristics and long-term outcomes after operative decompression. J Neurosurg Spine 2018;28:621-9. [PMID: 29570047 DOI: 10.3171/2017.10.SPINE17821] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
46 Peeters K, Chamova T, Jordanova A. Clinical and genetic diversity of SMN1-negative proximal spinal muscular atrophies. Brain 2014;137:2879-96. [PMID: 24970098 DOI: 10.1093/brain/awu169] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
47 Watson KS, Boukhloufi I, Bowerman M, Parson SH. The Relationship between Body Composition, Fatty Acid Metabolism and Diet in Spinal Muscular Atrophy. Brain Sci 2021;11:131. [PMID: 33498293 DOI: 10.3390/brainsci11020131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Bertelli L, Nardo GD, Cazzato S, Ricci G, Pession A. Free-Aspire: A new device for the management of airways clearance in patient with ineffective cough. Pediatr Rep 2017;9:7270. [PMID: 29081932 DOI: 10.4081/pr.2017.7270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Cleary Y, Gertz M, Grimsey P, Günther A, Heinig K, Ogungbenro K, Aarons L, Galetin A, Kletzl H. Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy. Clin Pharmacol Ther 2021. [PMID: 34347881 DOI: 10.1002/cpt.2384] [Reference Citation Analysis]
50 Dolitsky S, Mitra A, Khan S, Ashkinadze E, Sauer MV. Beyond the "Jewish panel": the importance of offering expanded carrier screening to the Ashkenazi Jewish population. F S Rep 2020;1:294-8. [PMID: 34223259 DOI: 10.1016/j.xfre.2020.08.001] [Reference Citation Analysis]
51 Bertoli S, De Amicis R, Bedogni G, Foppiani A, Leone A, Ravella S, Mastella C, Baranello G, Masson R, Bertini E, D'Amico A, Pedemonte M, Bruno C, Agosto C, Giaquinto E, Bassano M, Battezzati A. Predictive energy equations for spinal muscular atrophy type I children. Am J Clin Nutr 2020;111:983-96. [PMID: 32145012 DOI: 10.1093/ajcn/nqaa009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
52 Srivastava G, Srivastava P. Spinal muscular atrophy – a revisit of the diagnosis and treatment modalities. International Journal of Neuroscience 2019;129:1103-18. [DOI: 10.1080/00207454.2019.1635128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Messina S, Sframeli M. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. J Clin Med 2020;9:E2222. [PMID: 32668756 DOI: 10.3390/jcm9072222] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 26.0] [Reference Citation Analysis]
54 Baranello G, Gorni K, Daigl M, Kotzeva A, Evans R, Hawkins N, Scott DA, Mahajan A, Muntoni F, Servais L. Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy. Clin Pharmacol Ther 2021. [PMID: 33792051 DOI: 10.1002/cpt.2247] [Reference Citation Analysis]
55 Faravelli I, Meneri M, Saccomanno D, Velardo D, Abati E, Gagliardi D, Parente V, Petrozzi L, Ronchi D, Stocchetti N, Calderini E, D'Angelo G, Chidini G, Prandi E, Ricci G, Siciliano G, Bresolin N, Comi GP, Corti S, Magri F, Govoni A. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients. J Cell Mol Med 2020;24:3034-9. [PMID: 32032473 DOI: 10.1111/jcmm.14939] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
56 Karolczak J, Weis S, Ehler E, Kierdaszuk B, Berdyński M, Zekanowski C, Kamińska AM, Rędowicz MJ. Myosin VI localization and expression in striated muscle pathology. Anat Rec (Hoboken) 2014;297:1706-13. [PMID: 25125183 DOI: 10.1002/ar.22967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
57 Wei Y, McCormick A, MacKenzie A, O'Ferrall E, Venance S, Mah JK, Selby K, McMillan HJ, Smith G, Oskoui M, Hogan G, McAdam L, Mabaya G, Hodgkinson V, Lounsberry J, Korngut L, Campbell C. The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities. Paediatr Child Health 2018;23:20-6. [PMID: 29479275 DOI: 10.1093/pch/pxx125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
58 Toossi A, Bergin B, Marefatallah M, Parhizi B, Tyreman N, Everaert DG, Rezaei S, Seres P, Gatenby JC, Perlmutter SI, Mushahwar VK. Comparative neuroanatomy of the lumbosacral spinal cord of the rat, cat, pig, monkey, and human. Sci Rep 2021;11:1955. [PMID: 33479371 DOI: 10.1038/s41598-021-81371-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Abati E, Citterio G, Bresolin N, Comi GP, Corti S. Glial cells involvement in spinal muscular atrophy: Could SMA be a neuroinflammatory disease? Neurobiol Dis 2020;140:104870. [PMID: 32294521 DOI: 10.1016/j.nbd.2020.104870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
60 Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N. The economic burden of spinal muscular atrophy. J Med Econ 2016;19:822-6. [PMID: 27264163 DOI: 10.1080/13696998.2016.1198355] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
61 Ho JK, Borle K, Dragojlovic N, Dhillon M, Kitchin V, Kopac N, Ross C, Lynd LD. Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review. Pharmacoeconomics 2021;39:995-1019. [PMID: 34156648 DOI: 10.1007/s40273-021-01051-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Fernández RM, Peciña A, Muñoz-cabello B, Antiñolo G, Borrego S. Co-segregation of a homozygous SMN1 deletion and a heterozygous PMP22 duplication in a patient. Clin Case Rep 2016;4:879-84. [DOI: 10.1002/ccr3.645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
63 Sabitha KR, Shetty AK, Upadhya D. Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies. Neurosci Biobehav Rev 2021;121:201-19. [PMID: 33370574 DOI: 10.1016/j.neubiorev.2020.12.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Gandhi G, Abdullah S, Foead AI, Yeo WWY. The potential role of miRNA therapies in spinal muscle atrophy. J Neurol Sci 2021;427:117485. [PMID: 34015517 DOI: 10.1016/j.jns.2021.117485] [Reference Citation Analysis]
65 Ramirez A, Crisafulli SG, Rizzuti M, Bresolin N, Comi GP, Corti S, Nizzardo M. Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy. Int J Mol Sci 2018;19:E167. [PMID: 29316633 DOI: 10.3390/ijms19010167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
66 Coratti G, Pane M, Lucibello S, Pera MC, Pasternak A, Montes J, Sansone VA, Duong T, Dunaway Young S, Messina S, D'Amico A, Civitello M, Glanzman AM, Bruno C, Salmin F, Tacchetti P, Carnicella S, Sframeli M, Antonaci L, Frongia AL, De Vivo DC, Darras BT, Day J, Bertini E, Muntoni F, Finkel R, Mercuri E; iSMAC group. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen. Neuromuscul Disord 2021;31:596-602. [PMID: 34099377 DOI: 10.1016/j.nmd.2021.03.012] [Reference Citation Analysis]
67 Vry J, Schubert IJ, Semler O, Haug V, Schönau E, Kirschner J. Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy. European Journal of Paediatric Neurology 2014;18:140-9. [DOI: 10.1016/j.ejpn.2013.09.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
68 Pera MC, Coratti G, Berti B, D'Amico A, Sframeli M, Albamonte E, de Sanctis R, Messina S, Catteruccia M, Brigati G, Antonaci L, Lucibello S, Bruno C, Sansone VA, Bertini E, Tiziano D, Pane M, Mercuri E. Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? PLoS One 2020;15:e0230677. [PMID: 32203538 DOI: 10.1371/journal.pone.0230677] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
69 Ricci F, Vacchetti M, Brusa C, Vercelli L, Davico C, Vitiello B, Mongini T. New pharmacotherapies for genetic neuromuscular disorders: opportunities and challenges. Expert Review of Clinical Pharmacology 2019;12:757-70. [DOI: 10.1080/17512433.2019.1634543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal Muscular Atrophy. Semin Pediatr Neurol 2021;37:100878. [PMID: 33892848 DOI: 10.1016/j.spen.2021.100878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Yuan P, Jiang L. Clinical characteristics of three subtypes of spinal muscular atrophy in children. Brain and Development 2015;37:537-41. [DOI: 10.1016/j.braindev.2014.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
72 Morelli KH, Hatton CL, Harper SQ, Burgess RW. Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next. Brain Res 2020;1732:146683. [PMID: 32001243 DOI: 10.1016/j.brainres.2020.146683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
73 Wasserman HM, Hornung LN, Stenger PJ, Rutter MM, Wong BL, Rybalsky I, Khoury JC, Kalkwarf HJ. Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity. Neuromuscul Disord 2017;27:331-7. [PMID: 28258940 DOI: 10.1016/j.nmd.2017.01.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
74 Souza PVS, Pinto WBVR, Ricarte A, Badia BML, Seneor DD, Teixeira DT, Caetano L, Gonçalves EA, Chieia MAT, Farias IB, Bertini E, Oliveira ASB. Clinical and radiological profile of patients with spinal muscular atrophy type 4. Eur J Neurol 2021;28:609-19. [PMID: 33090613 DOI: 10.1111/ene.14587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
75 Kizina K, Stolte B, Totzeck A, Bolz S, Schlag M, Ose C, von Velsen O, Kleinschnitz C, Hagenacker T. Fatigue in adults with spinal muscular atrophy under treatment with nusinersen. Sci Rep 2020;10:11069. [PMID: 32632203 DOI: 10.1038/s41598-020-68051-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
76 Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis 2021;16:36. [PMID: 33472673 DOI: 10.1186/s13023-020-01667-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Mazzone E, De Sanctis R, Fanelli L, Bianco F, Main M, van den Hauwe M, Ash M, de Vries R, Fagoaga Mata J, Schaefer K, D'Amico A, Colia G, Palermo C, Scoto M, Mayhew A, Eagle M, Servais L, Vigo M, Febrer A, Korinthenberg R, Jeukens M, de Viesser M, Totoescu A, Voit T, Bushby K, Muntoni F, Goemans N, Bertini E, Pane M, Mercuri E. Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. Neuromuscul Disord 2014;24:347-52. [PMID: 24491485 DOI: 10.1016/j.nmd.2014.01.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
78 Boido M, Vercelli A. Neuromuscular Junctions as Key Contributors and Therapeutic Targets in Spinal Muscular Atrophy. Front Neuroanat 2016;10:6. [PMID: 26869891 DOI: 10.3389/fnana.2016.00006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
79 Dangouloff T, Vrščaj E, Servais L, Osredkar D; SMA NBS World Study Group. Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go. Neuromuscul Disord 2021;31:574-82. [PMID: 33985857 DOI: 10.1016/j.nmd.2021.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
80 Faravelli I, Bucchia M, Rinchetti P, Nizzardo M, Simone C, Frattini E, Corti S. Motor neuron derivation from human embryonic and induced pluripotent stem cells: experimental approaches and clinical perspectives. Stem Cell Res Ther 2014;5:87. [PMID: 25157556 DOI: 10.1186/scrt476] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
81 Osmanovic A, Wieselmann G, Mix L, Siegler HA, Kumpe M, Ranxha G, Wurster CD, Steinke A, Ludolph AC, Kopp B, Lulé D, Petri S, Schreiber-Katz O. Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis. Brain Sci 2020;11:E8. [PMID: 33374658 DOI: 10.3390/brainsci11010008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
82 Cea LA, Riquelme MA, Cisterna BA, Puebla C, Vega JL, Rovegno M, Sáez JC. Connexin- and pannexin-based channels in normal skeletal muscles and their possible role in muscle atrophy. J Membr Biol 2012;245:423-36. [PMID: 22850938 DOI: 10.1007/s00232-012-9485-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
83 Mercuri E, Lucibello S, Pera MC, Carnicella S, Coratti G, de Sanctis R, Messina S, Mazzone E, Forcina N, Fanelli L, Norcia G, Antonaci L, Frongia AL, Pane M. Long-term progression in type II spinal muscular atrophy: A retrospective observational study. Neurology 2019;93:e1241-7. [PMID: 31451515 DOI: 10.1212/WNL.0000000000008166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
84 Walter LM, Rademacher S, Pich A, Claus P. Profilin2 regulates actin rod assembly in neuronal cells. Sci Rep 2021;11:10287. [PMID: 33986363 DOI: 10.1038/s41598-021-89397-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Lin C, Kalb SJ, Yeh W. Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review. Pediatric Neurology 2015;53:293-300. [DOI: 10.1016/j.pediatrneurol.2015.06.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
86 Biliouris K, Gaitonde P, Yin W, Norris DA, Wang Y, Henry S, Fey R, Nestorov I, Schmidt S, Rogge M, Lesko LJ, Trame MN. A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. CPT Pharmacometrics Syst Pharmacol 2018;7:581-92. [PMID: 30043511 DOI: 10.1002/psp4.12323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
87 Han YJ, Park JD, Lee B, Choi YH, Suh DI, Lim BC, Chae JH. Home mechanical ventilation in childhood-onset hereditary neuromuscular diseases: 13 years' experience at a single center in Korea. PLoS One 2015;10:e0122346. [PMID: 25822836 DOI: 10.1371/journal.pone.0122346] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
88 Wang Y, Zhu X, Yan Z, Zhi X, Guan S, Kuo Y, Nie Y, Lian Y, Huang J, Wei Y, Liu P, Li R, Qiao J, Yan L. Novel PGD strategy based on single sperm linkage analysis for carriers of single gene pathogenic variant and chromosome reciprocal translocation. J Assist Reprod Genet 2020;37:1239-50. [PMID: 32350783 DOI: 10.1007/s10815-020-01753-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Bielsky AR, Fuhr PG, Parsons JA, Yaster M. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen. Paediatr Anaesth 2018;28:1105-8. [PMID: 30284761 DOI: 10.1111/pan.13500] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
90 Haaker G, Fujak A. Proximal spinal muscular atrophy: current orthopedic perspective. Appl Clin Genet 2013;6:113-20. [PMID: 24399883 DOI: 10.2147/TACG.S53615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
91 Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin 2015;33:831-46. [PMID: 26515624 DOI: 10.1016/j.ncl.2015.07.004] [Cited by in Crossref: 182] [Cited by in F6Publishing: 129] [Article Influence: 36.4] [Reference Citation Analysis]
92 Vai S, Bianchi ML, Moroni I, Mastella C, Broggi F, Morandi L, Arnoldi MT, Bussolino C, Baranello G. Bone and Spinal Muscular Atrophy. Bone 2015;79:116-20. [PMID: 26055105 DOI: 10.1016/j.bone.2015.05.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
93 Yčas JW. Toward a Blood-Borne Biomarker of Chronic Hypoxemia: Red Cell Distribution Width and Respiratory Disease. Elsevier; 2017. pp. 105-97. [DOI: 10.1016/bs.acc.2017.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
94 Genabai NK, Ahmad S, Zhang Z, Jiang X, Gabaldon CA, Gangwani L. Genetic inhibition of JNK3 ameliorates spinal muscular atrophy. Hum Mol Genet 2015;24:6986-7004. [PMID: 26423457 DOI: 10.1093/hmg/ddv401] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
95 Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy. Ann Pharmacother 2020;54:1001-9. [DOI: 10.1177/1060028020914274] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
96 Sergott RC, Amorelli GM, Baranello G, Barreau E, Beres S, Kane S, Mercuri E, Orazi L, SantaMaria M, Tremolada G, Santarsiero D, Waskowska A, Yashiro S, Denk N, Fürst-Recktenwald S, Gerber M, Gorni K, Jaber B, Jacobsen B, Mueller L, Nave S, Scalco RS, Marzoli SB; FIREFISH, SUNFISH, JEWELFISH Working Groups. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol 2021;8:54-65. [PMID: 33231373 DOI: 10.1002/acn3.51239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
97 Sanderson AB, Novak JC, Nash SM, Kolb SJ, Kissel JT. Laboratory evaluation of suspected motor neuron disease: A survey of physicians: ALS Laboratory Workup Survey. Muscle Nerve 2015;52:83-7. [DOI: 10.1002/mus.24639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Caraballo-Miralles V, Cardona-Rossinyol A, Garcera A, Torres-Benito L, Soler RM, Tabares L, Lladó J, Olmos G. Notch signaling pathway is activated in motoneurons of spinal muscular atrophy. Int J Mol Sci 2013;14:11424-37. [PMID: 23759991 DOI: 10.3390/ijms140611424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
99 Jiang W, Ji X, Xu Y, Qu X, Sun W, Yang Z, Tao J, Chen Y. Molecular prenatal diagnosis of autosomal recessive spinal muscular atrophies using quantification polymerase chain reaction. Genet Test Mol Biomarkers 2013;17:438-42. [PMID: 23448387 DOI: 10.1089/gtmb.2012.0481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
100 Bulut N, Yardimci BN, Ayvat E, Aran OT, Yilmaz Ö, Karaduman A. The effect of two different aerobic training modalities in a child with spinal muscular atrophy type II: a case report. J Exerc Rehabil 2019;15:322-6. [PMID: 31111020 DOI: 10.12965/jer.1836604.302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Juntas Morales R, Pageot N, Taieb G, Camu W. Adult-onset spinal muscular atrophy: An update. Revue Neurologique 2017;173:308-19. [DOI: 10.1016/j.neurol.2017.03.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
102 Vilchis Z, Najera N, Pérez-duran J, Najera Z, Gonzalez L, del Refugio Rivera M, Queipo G. The high frequency of genetic diseases in hypotonic infants referred by neuropediatrics. Am J Med Genet 2014;164:1702-5. [DOI: 10.1002/ajmg.a.36543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
103 Babin PJ, Goizet C, Raldúa D. Zebrafish models of human motor neuron diseases: advantages and limitations. Prog Neurobiol 2014;118:36-58. [PMID: 24705136 DOI: 10.1016/j.pneurobio.2014.03.001] [Cited by in Crossref: 101] [Cited by in F6Publishing: 90] [Article Influence: 14.4] [Reference Citation Analysis]
104 Luu KT, Norris DA, Gunawan R, Henry S, Geary R, Wang Y. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations. J Clin Pharmacol 2017;57:1031-41. [PMID: 28369979 DOI: 10.1002/jcph.884] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
105 Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443-452. [PMID: 22516079 DOI: 10.1016/s1474-4422(12)70061-3] [Cited by in Crossref: 181] [Cited by in F6Publishing: 63] [Article Influence: 20.1] [Reference Citation Analysis]
106 Puhl DL, D'Amato AR, Gilbert RJ. Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Res Bull 2019;150:216-30. [PMID: 31173859 DOI: 10.1016/j.brainresbull.2019.05.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
107 Ahmadpour‐yazdi H, Hormozi‐nezhad MR, Abadi AR, Sanati MH, Kazemi B. Colourimetric‐based method for the diagnosis of spinal muscular atrophy using gold nanoprobes. IET nanobiotechnol 2015;9:5-10. [DOI: 10.1049/iet-nbt.2013.0065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
108 Bladen CL, Thompson R, Jackson JM, Garland C, Wegel C, Ambrosini A, Pisano P, Walter MC, Schreiber O, Lusakowska A, Jedrzejowska M, Kostera-Pruszczyk A, van der Pol L, Wadman RI, Gredal O, Karaduman A, Topaloglu H, Yilmaz O, Matyushenko V, Rasic VM, Kosac A, Karcagi V, Garami M, Herczegfalvi A, Monges S, Moresco A, Chertkoff L, Chamova T, Guergueltcheva V, Butoianu N, Craiu D, Korngut L, Campbell C, Haberlova J, Strenkova J, Alejandro M, Jimenez A, Ortiz GG, Enriquez GV, Rodrigues M, Roxburgh R, Dawkins H, Youngs L, Lahdetie J, Angelkova N, Saugier-Veber P, Cuisset JM, Bloetzer C, Jeannet PY, Klein A, Nascimento A, Tizzano E, Salgado D, Mercuri E, Sejersen T, Kirschner J, Rafferty K, Straub V, Bushby K, Verschuuren J, Beroud C, Lochmüller H. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol 2014;261:152-63. [PMID: 24162038 DOI: 10.1007/s00415-013-7154-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
109 Pera MC, Coratti G, Bovis F, Pane M, Pasternak A, Montes J, Sansone VA, Dunaway Young S, Duong T, Messina S, Mizzoni I, D'Amico A, Civitello M, Glanzman AM, Bruno C, Salmin F, Morando S, De Sanctis R, Sframeli M, Antonaci L, Frongia AL, Rohwer A, Scoto M, De Vivo DC, Darras BT, Day J, Martens W, Patanella KA, Bertini E, Muntoni F, Finkel R, Mercuri E; iSMAC group. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Ann Clin Transl Neurol 2021;8:1622-34. [PMID: 34165911 DOI: 10.1002/acn3.51411] [Reference Citation Analysis]
110 Jędrzejowska M, Gos M, Zimowski JG, Kostera-Pruszczyk A, Ryniewicz B, Hausmanowa-Petrusewicz I. Novel point mutations in survival motor neuron 1 gene expand the spectrum of phenotypes observed in spinal muscular atrophy patients. Neuromuscul Disord 2014;24:617-23. [PMID: 24844453 DOI: 10.1016/j.nmd.2014.04.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
111 Abera MB, Xiao J, Nofziger J, Titus S, Southall N, Zheng W, Moritz KE, Ferrer M, Cherry JJ, Androphy EJ, Wang A, Xu X, Austin C, Fischbeck KH, Marugan JJ, Burnett BG. ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight 2016;1:e88427. [PMID: 27882347 DOI: 10.1172/jci.insight.88427] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
112 Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, Corti S. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clin Ther 2014;36:128-40. [PMID: 24360800 DOI: 10.1016/j.clinthera.2013.11.006] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 7.4] [Reference Citation Analysis]
113 Wang J, Schultz PG, Johnson KA. Mechanistic studies of a small-molecule modulator of SMN2 splicing. Proc Natl Acad Sci U S A 2018;115:E4604-12. [PMID: 29712837 DOI: 10.1073/pnas.1800260115] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 16.3] [Reference Citation Analysis]
114 Larson JL, Silver AJ, Chan D, Borroto C, Spurrier B, Silver LM. Validation of a high resolution NGS method for detecting spinal muscular atrophy carriers among phase 3 participants in the 1000 Genomes Project. BMC Med Genet 2015;16:100. [PMID: 26510457 DOI: 10.1186/s12881-015-0246-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
115 Walter MC, Dräger B, Günther R, Hermann A, Hagenacker T, Kleinschnitz C, Löscher W, Meyer T, Schrank B, Schwersenz I, Wurster CD, Ludolph AC, Kirschner J. [Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience]. Nervenarzt 2019;90:343-51. [PMID: 30617569 DOI: 10.1007/s00115-018-0653-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Coratti G, Messina S, Lucibello S, Pera MC, Montes J, Pasternak A, Bovis F, Exposito Escudero J, Mazzone ES, Mayhew A, Glanzman AM, Young SD, Salazar R, Duong T, Muni Lofra R, De Sanctis R, Carnicella S, Milev E, Civitello M, Pane M, Scoto M, Bettolo CM, Antonaci L, Frongia A, Sframeli M, Vita GL, D'amico A, Van Den Hauwe M, Albamonte E, Goemans N, Darras BT, Bertini E, Sansone V, Day J, Nascimento Osorio A, Bruno C, Muntoni F, De Vivo DC, Finkel RS, Mercuri E. Clinical Variability in Spinal Muscular Atrophy Type III. Ann Neurol 2020;88:1109-17. [DOI: 10.1002/ana.25900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
117 Gray K, Isaacs D, Kilham HA, Tobin B. Spinal muscular atrophy type I: do the benefits of ventilation compensate for its burdens? J Paediatr Child Health. 2013;49:807-812. [PMID: 24131113 DOI: 10.1111/jpc.12386] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
118 Islander G, Brandom B. Anesthesia and spinal muscle atrophy. Paediatr Anaesth 2013;23:804-16. [DOI: 10.1111/pan.12159] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
119 Deik A, Saunders-Pullman R. Atypical presentation of late-onset Tay-Sachs disease. Muscle Nerve 2014;49:768-71. [PMID: 24327357 DOI: 10.1002/mus.24146] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
120 Kefalakes E, Sarikidi A, Bursch F, Ettcheto M, Schmuck M, Rumpel R, Grothe C, Petri S. Isoform-selective as opposed to complete depletion of fibroblast growth factor 2 (FGF-2) has no major impact on survival and gene expression in SOD1G93A amyotrophic lateral sclerosis mice. Eur J Neurosci 2019;50:3028-45. [PMID: 30883949 DOI: 10.1111/ejn.14405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Okamoto K, Fukuda M, Saito I, Urate R, Maniwa S, Usui D, Motoki T, Jogamoto T, Aibara K, Hosokawa T, Konishi Y, Arakawa R, Mori K, Ishii E, Saito K, Nishio H. Incidence of infantile spinal muscular atrophy on Shikoku Island of Japan. Brain and Development 2019;41:36-42. [DOI: 10.1016/j.braindev.2018.07.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
122 Farooq F, Abadía-Molina F, MacKenzie D, Hadwen J, Shamim F, O'Reilly S, Holcik M, MacKenzie A. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Hum Mol Genet 2013;22:3415-24. [PMID: 23656793 DOI: 10.1093/hmg/ddt191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
123 Bozorg Qomi S, Asghari A, Salmaninejad A, Mojarrad M. Spinal Muscular Atrophy and Common Therapeutic Advances. Fetal Pediatr Pathol 2019;38:226-38. [PMID: 31060440 DOI: 10.1080/15513815.2018.1520374] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
124 Travlos V, Downs J, Wilson A, Hince D, Patman S. Mental wellbeing in non-ambulant youth with neuromuscular disorders: What makes the difference? Neuromuscular Disorders 2019;29:48-58. [DOI: 10.1016/j.nmd.2018.08.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
125 Michelson D, Ciafaloni E, Ashwal S, Lewis E, Narayanaswami P, Oskoui M, Armstrong MJ. Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018;91:923-33. [PMID: 30315070 DOI: 10.1212/WNL.0000000000006502] [Cited by in Crossref: 51] [Cited by in F6Publishing: 20] [Article Influence: 17.0] [Reference Citation Analysis]
126 Maruotti GM, Sarno L, Simioli S, Castaldo G, Martinelli P. Prenatal screening and counseling for genetic disorders. J Matern Fetal Neonatal Med 2013;26 Suppl 2:68-71. [PMID: 24059557 DOI: 10.3109/14767058.2013.829701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
127 Choi S, Ferrari G, Tedesco FS. Cellular dynamics of myogenic cell migration: molecular mechanisms and implications for skeletal muscle cell therapies. EMBO Mol Med 2020;12:e12357. [PMID: 33210465 DOI: 10.15252/emmm.202012357] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
128 Silvinato A, Bernardo WM; Brazilian Medical Association. Spinal muscular atrophy 5Q - Treatment with nusinersen. Rev Assoc Med Bras (1992) 2018;64:484-91. [PMID: 30304304 DOI: 10.1590/1806-9282.64.06.484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]